,,ii #aagth ,,congress #ast ,session ,s4 #adfg ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,april #bi1 #bjba,mr4 ,tester 7for himself and ,mr4 ,sullivan7 introduced the following bill2 which was read twice and referred to the ,committee on ,veterans' ,affairs ,a ,,bill ,to direct the ,secretary of ,veterans ,affairs to carry out a series of clinical trials on the effects of cannabis on certain health outcomes of veterans with chronic pain and post-traumatic stress disorder1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,,va ,medicinal ,cannabis ,research ,act of #bjba4 #b4 ,department of ,veterans ,affairs clinical trials on the effects of cannabis on certain health outcomes of veterans with chronic pain and post-traumatic stress disorder 7a7 ,clinical trials required 7#a7 ,in general ,the ,secretary of ,veterans ,affairs shall carry out a series of clinical trials on the effects of medical-grade cannabis on the health outcomes of covered veterans diagnosed with chronic pain and covered veterans diagnosed with post-traumatic stress disorder4 7#b7 ,required elements ,the clinical trials required by paragraph 7#a7 shall include-- 7,a7 with respect to covered veterans diagnosed with chronic pain1 an evaluation of the effects of the use of cannabis on-- 7i7 osteopathic pain 7including pain intensity and pain-related outcomes72 7ii7 the reduction or increase in opioid use or dosage2 7iii7 the reduction or increase in benzodiazepine use or dosage2 7iv7 the reduction or increase in alcohol use2 7v7 inflammation2 7vi7 sleep quality2 7vii7 agitation2 and 7viii7 quality of life2 7,b7 with respect to covered veterans diagnosed with post-traumatic stress disorder1 an evaluation of the effects of the use of cannabis on-- 7i7 the symptoms of post-traumatic stress disorder 7,,ptsd7 as established by or derived from the clinician administered ,,ptsd scale1 the ,,ptsd checklist1 the ,,ptsd symptom scale1 the post-traumatic diagnostic scale1 and other applicable methods of evaluating symptoms of post-traumatic stress disorder2 7ii7 the reduction or increase in benzodiazepine use or dosage2 7iii7 the reduction or increase in alcohol use2 7iv7 mood2 7v7 anxiety2 7vi7 social functioning2 7vii7 agitation2 7viii7 suicidal ideation2 and 7ix7 sleep quality1 including frequency of nightmares and night terrors4 7#c7 ,optional elements ,the clinical trials required by paragraph 7#a7 may include an evaluation of the effects of the use of cannabis to treat chronic pain and post-traumatic stress disorder on-- 7,a7 pulmonary function2 7,b7 cardiovascular events2 7,c7 head1 neck1 and oral cancer2 7,d7 testicular cancer2 7,e7 ovarian cancer2 7,f7 transitional cell cancer2 7,g7 intestinal inflammation2 7,h7 motor vehicle accidents2 7,i7 mania2 7,j7 psychosis2 7,k7 cognitive effects2 7,l7 cannabinoid hyperemesis syndrome2 7,m7 neuropathy2 or 7,n7 spasticity4 7b7 ,long-,term observational study ,the ,secretary may carry out a long-term observational study of the participants in the clinical trials required by subsection 7a74 7c7 ,type of cannabis 7#a7 ,in general ,in carrying out the clinical trials required by subsection 7a71 the ,secretary shall study varying forms of cannabis1 including whole plant raw material and extracts4 7#b7 ,plant cultivars ,of the varying forms of cannabis required under paragraph 7#a71 the ,secretary shall study not fewer than seven unique plant cultivars with ratios of tetrahydrocannabinol to cannabidiol in each of the following categories3 7,a7 ,less than #a3e4 7,b7 ,between #a3b and #a3e4 7,c7 ,approximately #a3b4 7,d7 ,approximately #a3a4 7,e7 ,approximately #b3a4 7,f7 ,between #b3a and #e3a4 7,g7 ,more than #e3a4 7d7 ,use of control and experimental groups ,the clinical trials required by subsection 7a7 shall include both a control group and an experimental group that shall-- 7#a7 be of similar size and structure2 and 7#b7 represent the demographics of the veteran population1 as determined by the most recent data from the ,american ,community ,survey of the ,bureau of the ,census that is available prior to the commencement of the clinical trials4 7e7 ,data preservation ,the clinical trials required by subsection 7a7 shall include a mechanism to ensure the preservation of all data1 including all data sets1 collected or used for purposes of such trials in a manner that will facilitate further research4 7f7 ,implementation ,not later than #ahj days after the date of the enactment of this ,act1 the ,secretary shall-- 7#a7 develop a plan to implement this section and submit such plan to the ,committee on ,veterans' ,affairs of the ,senate and the ,committee on ,veterans' ,affairs of the ,house of ,representatives2 and 7#b7 issue any requests for proposals the ,secretary determines appropriate for such implementation4 7g7 ,effect on other benefits ,the eligibility or entitlement of a covered veteran to any other benefit under the laws administered by the ,secretary or any other provision of law shall not be affected by the participation of the covered veteran in a clinical trial under subsection 7a7 or a study under subsection 7b74 7h7 ,periodic reports ,during the five-year period beginning on the date of the enactment of this ,act1 the ,secretary shall submit periodically1 but not less frequently than annually1 to the ,committee on ,veterans' ,affairs of the ,senate and the ,committee on ,veterans' ,affairs of the ,house of ,representatives reports on the implementation of this section4 7i7 ,covered veteran defined ,in this section1 the term covered veteran means a veteran who is enrolled in the patient enrollment system of the ,department of ,veterans ,affairs established and operated under section #agje7;a7 of title #ch1 ,united ,states ,code4